Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas.
Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas.
复制标题
DOI：
10.3390/jpm12020267
复制
发表时间：
2022-02-11
影响因子：
--
通讯作者：
Barta SK
中科院分区：
文献类型：
--
作者：
Angelos MG;Ballard HJ;Barta SK
外周t细胞淋巴瘤（PTCLs）是一种罕见的非霍奇金淋巴瘤的异质性亚群，其特点是具有侵袭性的临床病程。从历史上看，ptcl的治疗类似于侵袭性b细胞淋巴瘤的治疗；然而，已经确定的是，使用几乎相同的化疗策略，总体反应和完全缓解率要差得多。最近，有大量的新药物被设计用于区分特定PTCL亚型的细胞和分子特征。这些药物已被证明能产生优异的抗淋巴瘤反应，在某些情况下，在复发、难治性和一线治疗环境中，总生存率更高。在这篇综述中，我们将总结和强调导致美国食品和药物管理局（FDA）批准几种新型PTCL治疗药物的最具影响力的临床试验，重点介绍新兴研究和策略，以扩大其在一线治疗环境中的潜在应用。
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous subset of non-Hodgkin lymphoma characterized by an aggressive clinical course. Historically, the treatment of PTCLs have been analogous to that of aggressive B-cell lymphomas; however, it has been well-established that overall responses and complete remission rates are far inferior using near-identical chemotherapy strategies. Recently, there has been a plethora of newer agents designed to target distinguishing cellular and molecular features of specific PTCL subtypes. These agents have been proven to yield superior anti-lymphoma responses and, in some cases, overall survival in the relapsed, refractory, and frontline treatment setting. In this review, we will summarize and highlight the most influential clinical trials leading to the Food and Drug Administration (FDA) approval of several novel therapeutic agents against PTCL, with an emphasis on emerging studies and strategies to expand their potential use in the frontline treatment setting.
登录
查看更多内容
影响因子：
10.1
作者：
Bellei M;Foss FM;Shustov AR;Horwitz SM;Marcheselli L;Kim WS;Cabrera ME;Dlouhy I;Nagler A;Advani RH;Pesce EA;Ko YH;Martinez V;Montoto S;Chiattone C;Moskowitz A;Spina M;Biasoli I;Manni M;Federico M;International T-cell Project Network
通讯作者：
International T-cell Project Network
罗米地辛治疗复发/难治性外周 T 细胞淋巴瘤：关键研究更新表明持久反应。
影响因子：
28.5
作者：
Coiffier B;Pro B;Prince HM;Foss F;Sokol L;Greenwood M;Caballero D;Morschhauser F;Wilhelm M;Pinter-Brown L;Padmanabhan Iyer S;Shustov A;Nielsen T;Nichols J;Wolfson J;Balser B;Horwitz S
通讯作者：
Horwitz S
DOI：
10.1016/j.annonc.2021.12.002
发表时间：
2022-03
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
通讯作者：
--
影响因子：
20.3
作者：
Falchi, Lorenzo;Ma, Helen;O'Connor, Owen A.
通讯作者：
O'Connor, Owen A.
影响因子：
6.5
作者：
Foss, Francine;Advani, Ranjana;Pohlman, Brad
通讯作者：
Pohlman, Brad